PT  - JOURNAL ARTICLE
AU  - Matthew L. Meizlish
AU  - George Goshua
AU  - Yiwen Liu
AU  - Rebecca Fine
AU  - Kejal Amin
AU  - Eric Chang
AU  - Nicholas DeFilippo
AU  - Craig Keating
AU  - Yuxin Liu
AU  - Michael Mankbadi
AU  - Dayna McManus
AU  - Stephen Wang
AU  - Christina Price
AU  - Robert D. Bona
AU  - Cassius Iyad Ochoa Chaar
AU  - Hyung J. Chun
AU  - Alexander B. Pine
AU  - Henry M. Rinder
AU  - Jonathan Siner
AU  - Donna S. Neuberg
AU  - Kent A. Owusu
AU  - Alfred Ian Lee
TI  - Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis
AID  - 10.1101/2021.01.12.21249577
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.12.21249577
4099  - http://medrxiv.org/content/early/2021/01/15/2021.01.12.21249577.short
4100  - http://medrxiv.org/content/early/2021/01/15/2021.01.12.21249577.full
AB  - Background Thrombotic complications occur at high rates in hospitalized patients with COVID-19, yet the impact of intensive antithrombotic therapy on mortality is uncertain.Research Question How does in-hospital mortality compare with intermediate-versus prophylactic-dose anticoagulation, and separately with in-hospital aspirin versus no antiplatelet therapy, in treatment of COVID-19?Study Design and Methods Using data from 2785 hospitalized adult COVID-19 patients, we established two separate, nested cohorts of patients (1) who received intermediate- or prophylactic-dose anticoagulation (“anticoagulation cohort”, N = 1624), or (2) who were not on home antiplatelet therapy and received either in-hospital aspirin or no antiplatelet therapy (“aspirin cohort”, N = 1956). Propensity score matching utilizing various markers of illness severity and other patient-specific covariates yielded treatment groups with well-balanced covariates in each cohort. The primary outcome was cumulative incidence of in-hospital death.Results Among propensity score-matched patients in the anticoagulation cohort (N = 382), in a multivariable regression model, intermediate-compared to prophylactic-dose anticoagulation was associated with a significantly lower cumulative incidence of in-hospital death (hazard ratio 0.518 [0.308-0.872]). Among propensity-score matched patients in the aspirin cohort (N = 638), in a multivariable regression model, in-hospital aspirin compared to no antiplatelet therapy was associated with a significantly lower cumulative incidence of in-hospital death (hazard ratio 0.522 [0.336-0.812]).Interpretation In this propensity score-matched, observational study of COVID-19, intermediate-dose anticoagulation and aspirin were each associated with a lower cumulative incidence of in-hospital death.Summary conflict of interest statements No conflict of interest exists for any author on this manuscript.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a gift donation from Jack Levin and a separate anonymous donation to the Benign Hematology program at Yale, the DeLuca Foundation to fund hematology research at Yale, and the National Institutes of Health (grant HL142818 to H.J.C., and GM136651 and HL139116 to M.L.M.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Yale Institutional Review Board (HIC 2000027792). An additional, approved Data Use Agreement between Yale and Dana-Farber Cancer Institute permitted analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll authors have access to the data provided in this manuscript.